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The subclass B2 metallo--lactamase (MBL) Sfh-I from Serratia fonticola UTAD54 was cloned and overex-
pressed in Escherichia coli. The recombinant protein binds one equivalent of zinc, as shown by mass spec-
trometry, and preferentially hydrolyzes carbapenem substrates. However, compared to other B2 MBLs, Sfh-I
also shows limited hydrolytic activity against some additional substrates and is not inhibited by a second
equivalent of zinc. These data confirm Sfh-I to be a subclass B2 metallo--lactamase with some distinctive
properties.
Metallo--lactamases (MBLs) are zinc-dependent enzymes
of growing clinical concern (23). They hydrolyze carbapenems,
which are key antibiotics for resistant Gram-negative bacteria,
and are insusceptible to serine -lactamase inhibitors (7). Se-
quence information divides MBLs into three subclasses, B1,
B2, and B3 (13). Subclass B2, the least studied, includes CphA
(16, 20), ImiS (6, 24), and AsbM1 (25) from Aeromonas spp.
and Sfh-I (18) from the occasional pathogen Serratia fonticola
(4, 8, 14, 17). These are monozinc enzymes that strongly prefer
carbapenem substrates. Sfh-I (18) and a class A carbapen-
emase, SFC-1 (12, 15), are specific to S. fonticola strain
UTAD54. Sfh-I diverges markedly (58% ImiS and 60% CphA
sequence identity) from the Aeromonas B2 MBLs (18). Here
we expressed, purified, and biochemically characterized re-
combinant Sfh-I.
The complete blaSfh-I gene (GenBank accession no.
AF197943) (primers SfhFv4 [5-GGATCCCATATGAATAT
TAAATATTTATTTACGGCTG-3] and SfhRv2 [5-GTGCT
CGAGTTACTTAGGCGCCTTCTCAAGC-3]) and the frag-
ment encoding the expected mature protein (nucleotides 55 to
759; primers SfhFv3 [5-GGATCCCATATGTCTGAAAAAA
ACTTAACGCTTACC-3] and SfhRv2) were amplified by
PCR; the products were ligated into vector pET-26b (Nova-
gen), generating plasmids pSfh-Iv4 and pSfh-Iv3, respectively,
and the constructs were sequenced. Protein was expressed in
Escherichia coli BL21 Star (DE3) (Invitrogen) (37°C, M9Y
medium, 50 g/ml kanamycin, overnight induction [1 mM
IPTG] at 25°C) and purified by anion exchange (Q-Sepharose;
50 mM Tris-HCl, 100 M ZnCl2, pH 8.5) and size exclusion
(Superdex 75; 50 mM HEPES, pH 7.0) chromatography, yield-
ing approximately 50 mg/liter Sfh-I at 95% purity as ad-
judged by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE).
Sfh-I molecular mass and metal content characteristics were
investigated by electrospray mass spectrometry (QStar XL
qTOF system, positive-ion mode, nanoliter/minute sample de-
livery, Nanomate source [0.3 lb/in2, 1.4 kV]). The mass ob-
tained for Sfh-Iv3 under denaturing conditions (26,136 Da;
Fig. 1A) agreed with the value predicted (26,134 Da) from the
sequence after removal of the N-terminal methionine. A sim-
ilar result for Sfh-Iv4 confirmed removal of a 21-amino-acid
signal peptide (18). Additional peaks may represent oxidized
(26,136  16  26,152 Da [observed]) and subsequently hy-
drated (26,152  18  26,170 Da [observed]) adducts. In the
native spectrum (Fig. 1B), peaks at 26,201 Da (26,136  65
Da), 26,218 Da (26,152  66 Da), and 26,239 Da (26,170  69
Da) indicate additions of one equivalent of zinc (65 Da) to
species found under denaturing conditions. Thus, as isolated,
the Sfh-I was primarily mononuclear, as observed for CphA
and ImiS (6, 16) and in the Sfh-I crystal structures (Protein
Data Bank [PDB] accession no. 3Q6V and 3SD9) (11), and
typical of a B2 MBL.
-Lactam hydrolysis (50 mM HEPES, pH 7.0 [25°C]) was
investigated as described previously (19) (Table 1). Experi-
ments were performed in triplicate, recording data points every
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3 to 4 s for 20 to 30 min and adjusting concentrations to ensure
measurement of the linear phase of the reaction. Sfh-I effi-
ciently hydrolyzes carbapenems (imipenem and meropenem
kcat/Km  10
5 M1 s1) but resembles other B2 MBLs in its
low affinity (Km  300 M) and catalytic efficiency (kcat/Km 
103 M1 s1) for many penicillins and cephalosporins (9, 10,
20, 22, 24, 25). This is consistent with previous data showing
that Sfh-I expression in E. coli substantially elevated carba-
penem MICs but had little effect on those for other -lactams
(18). Sfh-I hydrolyzed benzylpenicillin, cefotaxime, cef-
tazidime, and sulbactam, but kinetic parameters for these sub-
strates could not be derived due to low affinities. Unexpectedly,
Sfh-I (0.01 M) hydrolyzed cefepime (against which 0.5 M
CphA shows no detectable activity [9]) with relatively high
efficiency. While differences between laboratories and experi-
mental conditions make comparison with data from previously
characterized B2 MBLs difficult, we note that the low affinity of
Sfh-I for penicillins is consistent with results seen with other
enzymes (possibly excepting AsbM1) and that higher kcat but
weaker Km values for hydrolysis of meropenem, compared to
imipenem, may be a general property of subclass B2 MBLs.
CphA is inactivated by cefoxitin, moxalactam, and other
cephalosporins with good 3 leaving groups (26). Cephalospo-
rin degradation products also inhibit the Bacillus cereus B1
MBL BcII (1). Whereas Sfh-I hydrolyzes cefoxitin, moxalac-
tam, and cephalothin with low efficiency (Table 1), at higher
concentrations each inhibited imipenem and nitrocefin hydro-
lysis. Interaction of Sfh-I with these compounds and their hy-
drolysis products was investigated. Although the mode of in-
hibition by the intact compounds was unclear, nitrocefin
hydrolysis assays showed that preincubation with cephalothin
or its hydrolysis product (purified by centrifugal filtration after
FIG. 1. Mass spectra of recombinant Sfh-I. (A) Spectrum acquired under denaturing conditions. (B) Spectrum acquired under nondenaturing
(native) conditions.
TABLE 1. Kinetic parameters of purified Sfh-I -lactamase and comparison with other B2 metallo--lactamasesa
Substrate
kcat (s
1) Km (M) kcat/Km (M
1 s1)
Sfh-I CphA AsbM1 ImiS Sfh-I CphA AsbM1 ImiS Sfh-I CphA AsbM1 ImiS
Ampicillin 9.5  1.11 	0.01b 0.13 1.1 676  187 2,500b 65 510 1.41 
 104 	4b 7.5 
 103 2.2 
 104
Benzylpenicillin ND 0.03 1.2 0.53 1,500 870 160 250 ND 35 2.0 
 103 2.1 
 103
Carbenicillin 9.15  1.58 10d 0.44 0.5 1,280  363 500d 28 260 7.18 
 103 2.0 
 104d 1.6 
 104 2.1 
 103
Nitrocefin 0.06  0.003 0.0028 0.02 0.024g 106  13.4 1,200 ND 51g 5.7 
 102 2.5 ND 4.0 
 103g
Cephaloridine 8.22 
 105  1.46 
 105 	0.006 0.06 NH 335  124.0 6,000 ND NH 2.46 
 101 	1 ND NH
Cephalothin NDh NR NR NR 84i NR NR NR ND NR NR NR
Cefotaxime ND 0.0002b NR NH 1,000 100b NR NH ND 2b NR NH
Ceftazidime ND NR NR NR 500 NR NR NR ND NR NR NR
Cefoxitin 0.032  0.00094 0.02e 0.06 NH 99  7 615e ND NH 3.23 
 102 33e ND NH
Cefepime 0.64  0.073 NH NR NR 202  43.7 NH NR NR 3.16 
 103 NH NR NR
Moxalactam 0.017  0.0012 NR NR NH 91  14 NR NR NR 1.87 
 102 5.6e NR NH
Sulbactam ND 0.12c NR NH 1,000 37c NR NH ND 3.2 
 103c NR NH
Imipenem 51  2.8 1,200 71 350f 79.2  11.2 340 230 100f 6.42 
 105 3.5 
 106 3.1 
 105 9.1 
 105f
Meropenem 109  9.5 3,100 220 296g 215  47.0 1,340 630 308g 5.05 
 105 2.3 
 106 3.5 
 105 3.3 
 106g
a Kinetic data displayed for CphA, AsbM1, and ImiS as reported by Vanhove et al. (22), Yang and Bush (25) and Walsh et al. (24), respectively, except where
otherwise indicated. ND, values could not be determined; NH, no hydrolysis detected; NR, not reported.
b As reported by Bebrone et al. (2).
c As reported by Felici et al. (10).
d As reported by Segatore et al. (20).
e As reported by Zervosen et al. (26).
f As reported by Sharma et al. (21).
g As reported by Crawford et al. (6).
h Value could not be determined due to inhibition at higher concentrations.
i Ki value determined from inhibition of nitrocefin hydrolysis.












hydrolysis using IMP-1 -lactamase) led to time-dependent
inactivation. Loss of Sfh-I activity correlated with cephalothin
hydrolysis, indicating that the hydrolysis product likely repre-
sents the inhibitory species. Incubating Sfh-I (3.6 M; 18 h;
25°C; 50 mM HEPES, pH 7.0) with various hydrolysis products
(1 mM) reduced hydrolysis of 200 M imipenem by 13%
(cefoxitin), 36% (cephalothin), and 94% (moxalactam). The
level of activity of cephalothin-treated samples remained at
54% of the control level, even after overnight dialysis, suggest-
ing inactivation by enzyme modification. Unfortunately, mass
spectrometry failed to identify the inhibitory species; while all
expected Sfh-I-derived peptides were detected, modified frag-
ments were not, suggesting a labile inhibitory complex. Previ-
ous workers suggested that the moxalactam hydrolysis product
covalently binds the CphA Cys-221 thiol (26). Association of
Cys-221 with the thiol of an opened dihydrothiazine ring of the
hydrolyzed cephalosporin (1), or addition to the exomethylene
formed upon elimination of the 3 leaving group, could also
explain the cephalothin inactivation of Sfh-I.
CphA is most active with a single tightly bound zinc ion (Kd1
	 20 nM) and weakly binds a second, inhibitory zinc (Kd2  46
M) (16). We used fluorescence spectroscopy (Jobin Yvon
FluoroLog) to investigate the Sfh-I–zinc interaction. Titration
of as-isolated (monozinc) Sfh-I with zinc (Fig. 2A) showed two
distinct transitions, demonstrating binding of two further
equivalents (Kd2, 95  14 M; Kd3, 2,300  870 M). The Kd2
value is comparable to that of binding of a second zinc to
CphA (46 M [16]). The third, low-affinity zinc (millimolar
Kd3) is unlikely to be physiologically relevant. (CphA binds a
third zinc at a surface site distinct from the active site [3].)
Other B2 MBLs are maximally active as monozinc enzymes,
with noncompetitive inhibition by a second zinc (6, 16, 25). The
effect of zinc addition on Sfh-I activity was substrate dependent
(Fig. 2B). Imipenem hydrolysis was unaffected by 400 M zinc,
while nitrocefinase activity increased due to an increased kcat
value. The midpoint (K) for activation (90  4 M) is equiv-
alent to Kd2, indicating that a second zinc activates nitrocefi-
nase activity. While zinc activates nitrocefin hydrolysis for
some CphA mutants (2), and the ImiS M146I mutation abol-
ishes zinc inhibition of imipenemase activity (5), the combina-
tion of zinc-dependent nitrocefinase activity and zinc-indepen-
dent imipenemase activity was not previously described.
Circular dichroism spectroscopy (Jasco-J810 spectropolarime-
ter) showed that the presence of a second zinc induced a small
increase in Sfh-I secondary structure (Fig. 2C) with little effect
on thermal stability (Tm for Sfh-I unfolding, 60°C; in 1 mM
zinc, 58°C; Fig. 2D).
In conclusion, Sfh-I is a monozinc enzyme with a strong
preference for carbapenems, confirming it to be a B2 MBL and
these to be common properties of the members of this sub-
group. However, Sfh-I differs from CphA, the most studied B2
MBL, in its activity toward cefepime and in the effect of addi-
FIG. 2. Effect of additional zinc on Sfh-I. (A) Change in Sfh-I intrinsic (tryptophan) fluorescence as a function of zinc concentration (50 mM
HEPES, pH 7.0; 25°C; excitation, 280 nm; emission, 341 nm). The solid line represents a fit of nitrocefin data to a two-site hyperbola model, with
Y (fluorescence)  Y2 
 [Zn
2]/(Kd2  [Zn
2])  Y3 
 [Zn
2]/(Kd3  [Zn
2]), where Y2 and Y3 represent the maximal fluorescence changes
associated with binding of a second and third zinc equivalent, corresponding to Kd2 (95  14 M) and Kd3 (2,300  870 M), respectively.
(B) Effect of added zinc on kcat/kcat0 (ratio of kcat at a given zinc concentration to kcat0 determined in the absence of excess zinc) for nitrocefin and
imipenem hydrolysis. The solid line represents a fit of nitrocefin data to kcat/kcat0  (K   
 [Zn
2])/([Zn2]  K), where  represents the value
of this ratio when the zinc concentration is at a saturating level (22). (C) Far-UV circular dichroism spectra (10 mM phosphate, pH 7.0; 25°C; 1-mm
cuvette) of Sfh-I (8.5 M) in the absence (solid line) and presence (dotted line) of 1 mM Zn2. (D) Second derivatives of plots of ellipticity (220
nm) against temperature for thermal unfolding of Sfh-I (8.5 M) in the absence (solid line) and presence (dotted line) of 1 mM Zn2.












tional zinc, indicating that not all B2 enzymes are inactivated
by excess zinc. Further investigations should establish the basis
for these differences.
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